High Resolution Mass Spectrometry and LC-UV Data Streams Applied to Characterizing Oligonucleotide Impurities

Importance of the Topic

Oligonucleotide therapeutics such as antisense and siRNA have emerged as powerful tools to modulate gene expression. Their complex molecular structure and closely related impurity profiles pose significant analytical challenges in quality control and regulatory environments. Comprehensive methods for sequence confirmation and impurity quantitation are essential to ensure product safety and efficacy.

Aims and Overview

This work presents an end-to-end analytical strategy that integrates high-resolution liquid chromatography–mass spectrometry (LC–MS) with UV/PDA detection and specialized data processing software. The goals are to confirm the sequence of a phosphorothioate 20mer (PS20mer), detect and characterize structural variants and low-level impurities, and compare performance between crude and purified samples.

Methodology and Instrumentation

The study employed ion-pair reversed-phase chromatography coupled to simultaneous high-resolution MS and UV/PDA acquisition. Insight Biologics software processed aligned LC–UV and MS data to match sequences, predict modifications, and quantify impurities.

Key methodological steps:

• Sample preparation: analysis of crude and purified PS20mer oligonucleotide samples
• Chromatographic separation: Shimadzu Nexera XSTM with Shim-pack Scepter Claris column using ion-pair mobile phases
• Mass spectrometry: Shimadzu QTOF LCMS-9050 operating in negative ion mode, acquiring TOF-MS (m/z 550–2500) and data-dependent MS/MS (m/z 100–2800) with a collision energy spread
• Data processing: Insight Biologics for extracted ion chromatograms, sequence matching, and impurity profiling

Used Instrumentation

• Shimadzu Nexera XSTM inert LC system
• Shim-pack Scepter Claris column (Contichrom CUBE)
• Shimadzu QTOF LCMS-9050 mass spectrometer

Main Results and Discussion

The workflow enabled detection and sequence confirmation of the full-length PS20mer alongside a comprehensive profile of shortmer impurities and modified variants. Purification reduced low-level impurities to below 0.1% relative abundance.

A focused comparison of the N-1(C1:G19) deletion impurity revealed a quantitative difference between UV/PDA (1.346%) and MS (1.63%), demonstrating the impact of ionization efficiency and co-detected analogs on accurate reporting. Data-dependent acquisition provided high sequence coverage in a single run.

Comparative profiling showed a significant reduction in impurity complexity after purification, validating the method’s sensitivity and specificity for routine QC.

Benefits and Practical Applications

• Simultaneous sequence confirmation and impurity profiling in one analysis
• High sensitivity for detecting impurities below 0.1% levels
• Automated data processing with target sequence matching and abundance calculation
• Applicable to QC workflows in oligonucleotide drug research, development, and manufacturing

Future Trends and Potential Applications

Advances in high-resolution MS, refined DDA strategies, and enhanced bioinformatic tools will further enhance sequence validation and impurity detection. Integration with orthogonal techniques such as ion mobility or NMR, along with machine learning for pattern recognition, will broaden analytical capabilities. Fully automated platforms and real-time data feedback will accelerate decision-making in research and quality assurance.

Conclusion

The described LC–UV coupled high-resolution MS workflow, supported by Insight Biologics software, offers a robust end-to-end solution for comprehensive characterization of oligonucleotide therapeutics and their impurities, delivering high sensitivity, detailed sequence coverage, and reliable quantitation.